CLOBETASOL PROPIONATE (EMOLLIENT) Drug Patent Profile

When do Clobetasol Propionate (emollient) patents expire, and when can generic versions of Clobetasol Propionate (emollient) launch?

Clobetasol Propionate (emollient) is a drug marketed by Ani Pharms, Beach Prods, Fougera Pharms, and Sun Pharma Canada. and is included in four NDAs.

The generic ingredient in CLOBETASOL PROPIONATE (EMOLLIENT) is clobetasol propionate. There are fourteen drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the clobetasol propionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Clobetasol Propionate (emollient)

A generic version of CLOBETASOL PROPIONATE (EMOLLIENT) was approved as clobetasol propionate by COSETTE on February 16^th, 1994.

Summary for CLOBETASOL PROPIONATE (EMOLLIENT)

US Patents:	0
Applicants:	4
NDAs:	4
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	79
Patent Applications:	3,865
DailyMed Link:	CLOBETASOL PROPIONATE (EMOLLIENT) at DailyMed

Pharmacology for CLOBETASOL PROPIONATE (EMOLLIENT)

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for CLOBETASOL PROPIONATE (EMOLLIENT)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	CLOBETASOL PROPIONATE (EMOLLIENT)	clobetasol propionate	CREAM;TOPICAL	075733-001	Aug 22, 2001		DISCN	No	No
Sun Pharma Canada	CLOBETASOL PROPIONATE (EMOLLIENT)	clobetasol propionate	CREAM;TOPICAL	075633-001	May 17, 2000	AB2	RX	No	No
Beach Prods	CLOBETASOL PROPIONATE (EMOLLIENT)	clobetasol propionate	CREAM;TOPICAL	209411-001	Aug 21, 2017	AB2	RX	No	No
Fougera Pharms	CLOBETASOL PROPIONATE (EMOLLIENT)	clobetasol propionate	CREAM;TOPICAL	075430-001	May 26, 1999	AB2	RX	No	Yes

Clobetasol Propionate (Emollient) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Market Overview and Key Drivers

Clobetasol propionate (emollient) is a potent topical corticosteroid used to treat inflammatory skin conditions. The global market for clobetasol propionate (emollient) is driven by the increasing prevalence of dermatological disorders, including eczema, psoriasis, and dermatitis. Technological advancements in drug delivery systems and the expanding healthcare infrastructure in emerging economies are also contributing to market growth. The market is characterized by a mix of branded and generic products, with pricing strategies and patent expiries playing a significant role in market competition.

Key market drivers include:

• Rising Incidence of Skin Diseases: A global increase in the prevalence of atopic dermatitis, psoriasis, and other inflammatory skin conditions fuels demand for effective topical treatments like clobetasol propionate. The World Allergy Organization (WAO) estimates that atopic dermatitis affects up to 20% of infants and 10% of adults globally. Psoriasis affects approximately 125 million people worldwide, with incidence rates varying by geographic region.
• Growing Healthcare Expenditure: Increased spending on healthcare globally, particularly in dermatology, translates to greater accessibility and demand for prescription medications. Government initiatives and private sector investments in healthcare infrastructure further support market expansion.
• Product Innovation and Formulation Development: Pharmaceutical companies are focusing on developing improved formulations of clobetasol propionate, such as creams, ointments, lotions, and gels with enhanced efficacy, reduced side effects, and better patient compliance. The development of emollient-based formulations aims to improve skin hydration and barrier function alongside the anti-inflammatory action of the corticosteroid.
• Aging Population: The demographic trend of an aging global population is associated with a higher susceptibility to chronic diseases, including various skin conditions, thereby increasing the patient pool for dermatological treatments.
• Demand for Generic Drugs: As patents for branded clobetasol propionate products expire, the entry of generic versions intensifies competition, leading to price reductions and increased market penetration, especially in price-sensitive markets. The global generic drugs market is projected to reach \$270.1 billion by 2027, according to some industry analyses.

Competitive Landscape and Key Players

The clobetasol propionate (emollient) market is moderately fragmented, with several global and regional players. Competition centers on product quality, pricing, regulatory approvals, and distribution networks. Key players are actively involved in research and development to introduce novel formulations and expand their market reach.

Major companies in the clobetasol propionate (emollient) market include:

• Dermik Laboratories (a Sanofi Company): Known for its branded clobetasol propionate products.
• Stiefel (a GSK Company): Offers various dermatological preparations, including those containing clobetasol propionate.
• Bausch Health Companies Inc.: A significant player in the dermatology space with clobetasol propionate offerings.
• Valeant Pharmaceuticals International, Inc. (now Bausch Health): Has historically held a strong position in dermatological products.
• Numerous Generic Pharmaceutical Manufacturers: Companies like Mylan N.V., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., and Accord Healthcare contribute significantly to the market through their generic offerings.

The market dynamics are influenced by mergers, acquisitions, and strategic partnerships aimed at consolidating market share and expanding product portfolios. For instance, the acquisition of dermatology assets by larger pharmaceutical companies often includes established clobetasol propionate products.

Patent Landscape and Expiry Trends

The patent landscape for clobetasol propionate itself is largely expired, as it is a well-established active pharmaceutical ingredient. However, patents can exist for specific formulations, delivery mechanisms, manufacturing processes, and combination therapies. The expiry of primary patents has facilitated the widespread availability of generic clobetasol propionate products, significantly impacting pricing and market accessibility.

• Original Compound Patents: The patents for the clobetasol propionate molecule itself have long expired. This is a common trajectory for older, well-established drugs.
• Formulation and Delivery System Patents: Innovation continues in developing novel formulations. Patents may cover specific emollient bases, enhanced penetration enhancers, sustained-release mechanisms, or unique combinations with other active ingredients. For example, a patent might claim a specific ratio of clobetasol propionate to a particular emollient mixture designed for improved skin feel and efficacy.
• Manufacturing Process Patents: Companies may hold patents for novel or more efficient methods of synthesizing clobetasol propionate or manufacturing its final dosage forms.
• Combination Therapy Patents: Patents might be filed for clobetasol propionate used in conjunction with other active ingredients to treat complex dermatological conditions, such as combining a corticosteroid with an antifungal or antibacterial agent.

The trend of patent expiries for the active ingredient has led to a robust generic market. This necessitates that companies focusing on clobetasol propionate (emollient) differentiate through formulation, branding, and market access rather than relying on long-term exclusivity based on the core compound.

Financial Trajectory and Market Value

The financial trajectory of the clobetasol propionate (emollient) market is characterized by steady growth, albeit with increasing price sensitivity due to generic competition. The market value is influenced by sales volume of both branded and generic products, pricing strategies, and regional demand.

• Market Size and Growth: The global topical corticosteroids market, of which clobetasol propionate is a significant component, is estimated to be worth billions of dollars. While specific figures for clobetasol propionate (emollient) alone are not always segregated, it represents a substantial segment within the potent corticosteroid category. The market is expected to continue its growth trajectory, driven by the aforementioned market drivers. Growth rates vary by region, with higher expansion anticipated in emerging markets due to improving healthcare access and rising disposable incomes.
• Pricing Dynamics: Branded clobetasol propionate products typically command higher prices. However, the influx of generic alternatives after patent expiry leads to significant price erosion. Generic clobetasol propionate (emollient) is considerably more affordable, making it accessible to a broader patient population and driving volume sales. This price competition is a defining characteristic of the market post-patent expiry.
• Revenue Streams: Revenue is generated from prescription sales through pharmacies and direct sales to healthcare institutions. Pharmaceutical companies derive income from both branded product sales and the manufacturing and distribution of generic versions. Contract manufacturing organizations (CMOs) also play a role, producing clobetasol propionate formulations for various pharmaceutical clients.
• Profitability: Profitability for branded products is higher due to premium pricing. For generic manufacturers, profitability is achieved through high sales volumes and efficient manufacturing processes that minimize production costs. Companies with strong supply chain management and robust distribution networks are better positioned to maintain healthy profit margins in the competitive generic space.

Regulatory Environment and Approvals

The regulatory environment for clobetasol propionate (emollient) is stringent, requiring approvals from health authorities like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national regulatory bodies. Approval processes focus on safety, efficacy, and quality of manufacturing.

• Key Regulatory Bodies:
  • FDA (United States): Approves new drug applications (NDAs) for branded products and abbreviated new drug applications (ANDAs) for generics. The FDA also oversees post-market surveillance and manufacturing standards. Clobetasol propionate is available in the U.S. in various strengths and formulations, including creams and ointments.
  • EMA (European Union): Oversees the centralized authorization procedure for medicines in the EU. National agencies also grant marketing authorizations.
  • Other National Agencies: Health Canada, Pharmaceuticals and Medical Devices Agency (Japan), Therapeutic Goods Administration (Australia), and national agencies in countries like India, Brazil, and China.
• Approval Pathways:
  • Branded Products: Require extensive clinical trials to demonstrate safety and efficacy.
  • Generic Products: Must demonstrate bioequivalence to the reference listed drug (RLD) and meet quality standards.
• Manufacturing Standards: Compliance with Good Manufacturing Practices (GMP) is mandatory for all manufacturers. Regulatory inspections ensure adherence to these standards.
• Labeling and Prescribing Information: Strict guidelines govern the labeling and prescribing information, including indications, contraindications, warnings, precautions, adverse reactions, and dosage. For potent corticosteroids like clobetasol propionate, warnings regarding potential side effects (e.g., skin atrophy, systemic absorption) are critical.

The regulatory landscape can impact market entry and ongoing commercialization. Companies must navigate these requirements to ensure their products meet the highest standards of quality and safety. Changes in regulatory policies, such as new pharmacovigilance requirements, can also influence market dynamics.

Challenges and Opportunities

The clobetasol propionate (emollient) market presents both challenges and opportunities for stakeholders.

Challenges:

• Generic Competition and Price Erosion: The most significant challenge is intense competition from generic manufacturers, leading to substantial price reductions and reduced profit margins for both branded and generic players.
• Side Effect Profile: Clobetasol propionate is a potent corticosteroid, and its use is associated with potential side effects, including skin thinning (atrophy), striae, and telangiectasias with prolonged or inappropriate use. Systemic absorption can also occur, particularly with large surface area application or occlusion, leading to potential hypothalamic-pituitary-adrenal (HPA) axis suppression. This limits its use for certain patient populations and duration of treatment.
• Regulatory Hurdles: Navigating complex and evolving regulatory pathways for new formulations or expanded indications can be time-consuming and costly.
• Increasing Demand for Biologics and Novel Therapies: The emergence of biologic drugs and other novel targeted therapies for inflammatory skin diseases may pose a long-term challenge to the market share of traditional topical treatments, especially for severe or refractory cases.

Opportunities:

• Development of Novel Formulations: Opportunities exist in developing advanced formulations that improve efficacy, reduce side effects, enhance patient compliance, and offer better cosmetic profiles. This includes microemulsions, nanocarriers, and combination therapies. Emollient bases that also provide therapeutic benefits (e.g., barrier repair) are particularly attractive.
• Emerging Markets: Growing healthcare infrastructure, increasing disposable incomes, and a rising awareness of dermatological conditions in emerging economies offer significant growth potential.
• Combination Products: Developing fixed-dose combination products with other therapeutic agents (e.g., antifungals, antibiotics, keratolytics) can address more complex skin conditions and create differentiated market offerings.
• Improved Patient Education and Adherence Programs: Initiatives focused on educating patients and healthcare providers about the appropriate and safe use of potent topical corticosteroids like clobetasol propionate can help mitigate side effect concerns and improve treatment outcomes, thereby sustaining demand.
• Cost-Effective Generic Manufacturing: For generic manufacturers, focusing on highly efficient and cost-effective manufacturing processes can ensure profitability and market share in a competitive landscape.

Key Takeaways

Clobetasol propionate (emollient) remains a cornerstone treatment for inflammatory dermatological conditions, driven by the persistent prevalence of diseases like eczema and psoriasis. The market is characterized by mature patent landscapes for the active ingredient, leading to robust generic competition and significant price pressures. Differentiation through innovative formulations, particularly those enhancing emollient properties for improved skin health and patient comfort, presents a key avenue for market growth. Emerging markets offer substantial expansion opportunities due to improving healthcare access. However, the inherent side effect profile of potent corticosteroids necessitates stringent regulatory oversight and a focus on safe and appropriate patient use.

FAQs

1. What is the primary therapeutic indication for clobetasol propionate (emollient)? Clobetasol propionate (emollient) is primarily indicated for the short-term management of more severe or intractable recalcitrant, inflammatory skin conditions that have not responded to milder corticosteroids. This includes conditions such as severe psoriasis, eczema, lichen planus, and discoid lupus erythematosus. The emollient base aims to enhance skin hydration and barrier function alongside the anti-inflammatory effects.

2. How does the emollient component impact the efficacy and application of clobetasol propionate? The emollient component of clobetasol propionate formulations aims to moisturize the skin, improve its barrier function, and reduce dryness and scaling associated with inflammatory skin conditions. It can also enhance the penetration of clobetasol propionate into the skin, potentially increasing its efficacy. Furthermore, emollient bases can improve the cosmetic feel and tolerability of the topical application, leading to better patient adherence.

3. What are the major concerns regarding the long-term use of clobetasol propionate? Long-term or excessive use of clobetasol propionate, a potent topical corticosteroid, can lead to several adverse effects. These include skin atrophy (thinning), striae (stretch marks), telangiectasias (spider veins), and depigmentation. More significantly, prolonged application over large body surface areas or under occlusion can result in systemic absorption, potentially leading to hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and other systemic corticosteroid-related side effects.

4. How has patent expiry affected the market for clobetasol propionate (emollient)? The expiry of primary patents for clobetasol propionate has led to the widespread availability of generic versions. This has significantly increased market competition, driving down prices and making the treatment more affordable and accessible. While this benefits consumers and healthcare systems through cost savings, it has also reduced profit margins for manufacturers of branded products and intensified the focus on volume sales and manufacturing efficiency for generic producers.

5. What are the future trends anticipated in the clobetasol propionate (emollient) market? Future trends are expected to include continued innovation in formulation development to enhance efficacy, reduce side effects, and improve patient experience, such as advanced emollient systems or novel delivery technologies. The market will likely see sustained growth in emerging economies due to expanding healthcare access and rising patient populations. There may also be a greater focus on combination therapies that address multiple aspects of inflammatory skin conditions, as well as increased efforts in patient and physician education to ensure appropriate and safe use of potent topical corticosteroids.

Citations

[1] World Allergy Organization. (n.d.). The burden of atopic dermatitis. Retrieved from https://www.worldallergy.org/educational-resources/atopic-dermatitis/burden-of-atopic-dermatitis [2] National Psoriasis Foundation. (n.d.). Psoriasis statistics. Retrieved from https://www.psoriasis.org/content/statistics [3] Grand View Research. (2021, October). Generic drugs market size, share & trends analysis report by drug type (branded generics, ... by region, and segment forecasts, 2021-2027. Retrieved from https://www.grandviewresearch.com/industry-analysis/generic-drugs-market (Note: Specific report details and access may vary. This is a representative citation for a market research firm covering the topic.) [4] U.S. Food and Drug Administration. (n.d.). Drugs@FDA. Retrieved from https://www.accessdata.fda.gov/scripts/cder/daf/ [5] European Medicines Agency. (n.d.). Medicines. Retrieved from https://www.ema.europa.eu/en/medicines